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Abstract
Background: Infestation with the human head louse (Pediculus humanus capitis) occurs worldwide.
Existing treatment options are limited, and reports of resistance to commonly used pediculicides
have been increasing. In this trial we assessed the efficacy of a product containing a high (92%)
concentration of the silicone oil dimeticone (identical in composition to NYDA®), as compared to
a 1% permethrin lotion.
Methods: Randomized, controlled, observer blinded clinical trial. Participants were recruited from
a poor urban neighbourhood in Brazil where pediculosis capitis was highly prevalent. To minimize
reinfestation during the trial, participants (145 children aged 5–15 years with head lice infestations)
were transferred to a holiday resort outside the endemic area for a period of 9 days. Two
applications of dimeticone or 1% permethrin were done, seven days apart. Outcome measures
were defined as cure (absence of vital head lice) after first application and before and after second
applications, degree of itching, cosmetic acceptability, and clinical pathology.
Results: Overall cure rates were: day 2 – dimeticone 94.5% (95% CI: 86.6% – 98.5%) and
permethrin 66.7% (95% CI: 54.6% – 77.3%; p < 0.0001); day 7 – dimeticone 64.4% (95% CI: 53.3%
– 75.3%) and permethrin 59.7% (95% CI: 47.5% – 71.1%; p = 0.5); day 9 – dimeticone 97.2% (95%
CI: 90.3% – 99.7%) and permethrin 67.6% (95% CI: 55.4%-78.2%); p < 0.0001). Itching was reduced
similarly in both groups. Cosmetic acceptability was significantly better in the dimeticone group as
compared to the permethrin group (p = 0.01). Two mild product-related incidents occurred in the
dimeticone group.
Conclusion: The dimeticone product is a safe and highly efficacious pediculicide. Due to its
physical mode of action (interruption of the lice's oxygen supply of the central nervous system),
development of resistance is unlikely.
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Background
Infestation with the human head louse (Pediculus humanus
capitis) occurs worldwide, and pediculosis capitis is hyper-
endemic in many resource-poor populations in the devel-
oping world [1,2]. In high income countries, head lice are
a problem mainly in school-aged children [3,4], with an
increasing number of reports of resistance to commonly
used pediculicides, such as permethrin and malathion [5-
13]. In addition, there is a growing public concern about
the potential hazards of pediculicides with a neurotoxic
mode of action. Thus, existing treatment options are lim-
ited.
Dimeticones (linear polydimethylsiloxanes of varying
chain length) are silicone oils with a low surface tension
and special creeping and spreading properties. They are a
new class of anti-head lice compounds with a physical
mode of action. It has recently been demonstrated that
NYDA® (Pohl-Boskamp GmbH & Co. KG, Hohenlockst-
edt, Germany), an anti-head lice product containing two
dimeticones with different viscosities in a total concentra-
tion of 92%, rapidly penetrated into the spiracles of lice.
The product filled the entire tracheal system within min-
utes, thereby interrupting oxygen supply and leading to
rapid death of the insect [14,15]. In addition, we recently
reported a high in vitro efficacy of NYDA® against adult
head lice [16]. The product is commercialized in Germany
and other European countries since 2006 and sold as an
over-the-counter medical device.
Two randomized controlled trials in the United Kingdom
showed that a product containing only 4% dimeticone
(Hedrin®) had a similar efficacy as d-phenotrin (0.5%),
with cure rates of about 70% [17], and a better efficacy
than malathion [18].
In the present observer blinded comparative trial we
assessed the efficacy of a product identical in composition
with NYDA® in comparison with 1% permethrin lotion
(Kwell®), in individuals recruited from an area where
pediculosis capitis is hyperendemic.
Methods
Participants, setting and eligibility criteria
Participants were recruited from a resource-poor commu-
nity in Fortaleza, the capital of Ceará State in northeast
Brazil. In the community, head lice infestations are very
common (prevalence in the general population > 40%).
In general, intensity of the infestation is high, and pedic-
ulosis capitis is associated with considerable morbidity
[1]. Children aged 5 – 15 years with a head lice infestation
were identified by community health care workers. Indi-
viduals were included in the study if one or more active
head lice were found by visual inspection. Visual inspec-
tions were done by a trained auxiliary nurse, following a
standardized procedure. It took three minutes, or was
interrupted earlier when 25 lice were found. Fine tooth
combing was not performed as a diagnostic test at this
stage, as combing would have reduced the number of
head lice present on the scalp and thereby bias cure rates.
We opted for a comparatively insensitive diagnostic
method (visual inspection) [19,20] to reduce the number
of individuals included with only few head lice on their
scalp and to select participants with a moderate or a high
intensity of infestation.
Individuals were not admitted to the study if one or more
of the following criteria were present:
- use of head lice products, anthelminthics, or antibiotics
within the previous four weeks;
- severe skin disorders of the scalp (such as generalized
impetigo, eczema, psoriasis or chronic dermatitis of
unknown origin);
- bleached or colour treated hair within the previous four
weeks;
- known sensitivity to any ingredients in the products;
- mental disease;
- drug abuse;
- pregnant or lactating girls;
- unwillingness to stay for 9 days in a holiday resort out-
side the endemic area where the clinical trial would be car-
ried out;
- participation in another clinical study in the previous
month.
Study location
As recent trials in the United Kingdom have shown rapid
reinfestation after cure [17,18] and because reinfestation
is known to occur very rapidly in the setting where partic-
ipants were recruited from (Pilger et al., manuscript sub-
mitted), participants were transferred to a holiday resort
outside the endemic area for a period of nine days. It was
expected that this would reduce the occurrence of re-infes-
tation.
Intervention
Participants with head lice were randomized to receive
either topical treatment with a product containing a high
percentage of dimeticones (92%), equivalent in composi-
tion to NYDA® (G. Pohl-Boskamp GmbH & Co. KG,
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Hohenlockstedt, Germany), or permethrin 1% lotion
(Kwell®, GlaxoSmithKline, Brazil). The first product was
prepared at the Department of Pharmacy of the Federal
University of Ceará by an experienced pharmacist, the lat-
ter bought locally at a pharmacy. As NYDA® was not regis-
tered as a medical device in Brazil, a parallel formulation
was produced locally. The product was prepared using the
identical constituents obtained from the same commer-
cial source as the components of the branded product
NYDA®. It was stored in 500 ml glass bottles and kept in a
refrigerator until use. Permethrin is commonly used in
Brazil and many other countries as a first line therapy for
head lice infestation. In the study area, permethrin resist-
ance has not been observed. However, there are no sys-
tematic studies available, and the resistance situation is
not fully understood (Heukelbach, unpublished observa-
tion).
Participants were treated immediately upon arrival at the
resort (day 1) and, according to the suggestion of a
Cochrane Expert Panel [21], a second time 7 days later
(day 8) to kill newly hatched lice from eggs which may
have survived the first treatment. The producers of both
products claim that the substances have an ovicidal effect.
The products were used according to the producers' rec-
ommendations. However, following a suggestion made
by Dodd [21], the fine tooth comb provided by both pro-
ducers together with the pediculicide was not used after
the application of the products. The dimeticone-based
product was applied to dry hair and then left to dry natu-
rally. After 8 hours the hair was washed with a commercial
shampoo not containing dimeticones. Permethrin was
applied to wet hair, left for 30 minutes and thereafter
washed out in an identical manner as dimeticone.
Both products were applied systematically onto the hair
from the hair shafts to the tips, and a normal comb was
used to spread the liquids evenly.
Objective
The trial was done to test the efficacy of a dimeticone-
based product chemically identical to NYDA® to cure head
lice infestations, in comparison to permethrin 1% lotion
(Kwell®).
Outcomes
The primary outcome measure was defined as the propor-
tion of participants cured of head lice infestation 1, 6 and
8 days after the first treatment (i.e. days 2, 7 and 9, respec-
tively).
Cure was defined as the complete absence of viable lice on
the scalp, as determined by wet combing with a high qual-
ity plastic head louse comb. This is considered a sensitive
method to diagnose active lice infestation [19]. Diagnos-
tic wet combing was performed after the application of a
commercially available conditioner without silicone oil.
Prior to the study, the conditioner had been tested in vitro
to exclude any pediculicidal effect (20 head lice were fully
coated with the conditioner, placed on a humid paper and
observed for vital signs). Diagnostic wet combing was per-
formed on day 2 (24 hours after first application), day 7
(one day before the second treatment) and day 9 (24
hours after second treatment). Head lice found were care-
fully removed and examined after 0.5 to 2 hours under a
dissecting microscope for vitality signs as described previ-
ously, and stringent criteria for mortality were used [16].
Secondary outcomes included the reduction of clinical
pathology, reduction of the degree of itching, cosmetic
acceptability of the products, and safety (number and type
of adverse events). The degree of itching was assessed
daily based on a pre-tested ordinal visual analogue scale
ranging from 0 to 4 (Figure 1). Cosmetic acceptability was
assessed using a summary score ranging from -4
(extremely negative) to +4 (extremely positive), using a
standardized questionnaire including subjective assess-
ment of smelling, irritation of scalp, cosmetic changes of
hair, and changes in the easiness to comb the hair. Clini-
cal pathology included the presence of erythema, papules,
excoriations, eczema, secondary infection and enlarged
cervical or retro-auricular lymph nodes.
The assessment of clinical pathology was made before
each application (days 1 and 9) and on days 2, 4 and 7.
Cosmetic acceptability was determined on days 2, 4, 7 and
9.
Assessors for cure rate, itching, clinical pathology, and
cosmetic acceptability were blinded regarding treatment
groups.
Participants were instructed to report any adverse events at
once and were specifically asked about possible adverse
events at assessments of cosmetic acceptability. All
adverse events reported by participants or noted by inves-
tigators during examination, and any inter-current illness
was recorded in an Adverse Event Report Form, regardless
whether or not they were considered to be related to the
intervention.
The final assessment was undertaken 24 hours after the
second treatment. If lice were found, they were removed
and collected for analysis of activity. Before leaving the
holiday resort, participants were treated with ivermectin
200 μg/kg in a single dose. In Brazil, oral ivermectin is a
registered treatment for pediculosis.
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Sample size
Assuming a cure rate of 80%, a study size of 62 partici-
pants would be needed per group to detect an absolute
difference of 25% in cure rates between treatment groups
(power = 80%). Considering loss to follow-up (children
who wanted to return from the holiday resort to their
homes during the study period) and possible post-rand-
omization protocol violations, a study size of about 70
participants per group was considered to be sufficient.
Random allocation
Participants had an equal probability of assignment to the
groups. The randomization code was created by an inves-
tigator not involved in assessment of outcome measures
or analysis of the study, using a computer generated ran-
dom list. Blocked randomisation was used with a block
length of six.
Blinding
The study was observer-blinded. As the two products
looked considerably different, had a different smell and
distinct cosmetic characteristics, a double-blinded design
was not possible. All study personnel directly or indirectly
involved in assessments of primary or secondary out-
comes were blinded to treatment assignment for the dura-
tion of the study. Only the auxiliary personnel who
applied the topical treatment and one investigator super-
vising the treatment had access to unblinded data.
Although complete blinding of the participants was not
possible, they were not informed to which treatment
groups they belonged to. Treatment and assessment of
outcome measures were done at distinct locations of the
holiday resort. During the study period each participant
carried an ID number in a badge so that no study partici-
pant could be mistaken for someone else.
Statistical methods
Data were entered twice into an Epi Info data base (ver-
sion 6.04d, CDC, Atlanta, USA) and cross-checked for
entry errors. Data analysis was done using STATA software
(version 9; Stata Corporation, College Station, USA).
Analysis was based on the intention-to-treat population.
The intention-to-treat population included all partici-
pants allocated to one treatment group and who received
at least the first treatment. Differences between the groups
in baseline characteristics, safety, cosmetic acceptability,
reduction of clinical pathology and efficacy was tested
using the chi squared test, the Fisher's exact test and the
Mann-Whitney test, where appropriate.
Ethical aspects
This study was conducted in accordance with the revised
Declaration of Helsinki. Each participant and his/her
guardian gave written informed consent after having
received an information leaflet and after a verbal explana-
tion of the objectives and the procedures of the study had
been given. At the end of the study, all participants were
treated with oral ivermectin to cure any persistent head
lice infestation, and to eliminate intestinal helminths.
Ivermectin is known to be an effective drug against a vari-
ety of ectoparasites and intestinal helminths [22,23].
The study was approved by the Ethical Review Board of
the Federal University of Ceará.
Assessment of degree of itching using an ordinal visual scale ranging from 0 to 4Figure 1
Assessment of degree of itching using an ordinal visual scale ranging from 0 to 4.
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Results
Recruitment
The trial was divided into two parts. Two holiday camps
were organized at the same resort in January 2007, each
with duration of nine days. Both camps were carried out
during school holidays. A total of 145 children aged 5 to
15 years agreed to participate. In the first camp, 77 indi-
viduals participated, and in the second 68. Conditions at
both camps were identical. Randomization was done only
once, before the beginning of the study. There was no dif-
ference in demographic or clinical characteristics of study
participants at both camps.
Participant flow (Figure 2)
The total number of participants assigned to the dimeti-
cone group was 73, and to the permethrin group 72. All
145 participants received two treatments. All participants
were examined for the primary outcome at days 2 and 7.
In each group, one participant was lost during follow-up.
Consequently, at day 9, 72 participants in the dimeticone
and 71 in the permethrin group were available for assess-
ment of cure.
Eight participants in the dimeticone group and five in the
permethrin group left the holiday resort during the study
period due to homesickness. They were visited in their
homes at the respective days to receive second treatment
and to assess primary and secondary outcome measures,
and were included in analysis. Their family members were
treated with ivermectin to reduce the occurrence of rein-
festation.
Baseline data
Both treatment groups were similar in age, sex, intensity of
infestation, and hair length (Table 1).
Cure rates
Cure rates in the dimeticone group were very high at days
2 and 9 and significantly better than in the permethrin
group. Cure rates at days 2, 7 and 9 are depicted in Table 2.
As an indicator for reinfestation, we assessed the presence
of adult lice on day 7 in the head louse-free population on
day 2. In the dimeticone group, of the 26 participants with
head lice on day 7, 24 had been classified as cured on day
2, and only 2 had head lice at both points of time. Of the
24 incident cases, 21 (87.5%) had adult head lice on their
scalps on day 7. In the permethrin group, there were 29
participants with head lice on day 7. Of these, 13 were not
infested on day 2, and 16 continued being infested. Of the
13 incident cases in this group, 12 (92.3%) had adult
head lice on their scalps on day 7.
Participants were stratified according to the number of
head lice found at the beginning of the study. Cure rates
were high in both treatment groups for participants with
low or moderate intensity of infestation, with a significant
higher efficacy of dimeticone at day 2 and day 9 (Table 3).
In heavy infestation (arbitrarily defined as ≥ 5 active head
lice after 3 min visual inspection), the cure rate remained
very high in the dimeticone group at days 2 and 9,
whereas in the permethrin group it was low.
In the dimeticone group, cure rates were similar at all
three assessments when stratified by hair length and sex.
Cure rates were also similar in the permethrin group at
days 2 and 7, but differed significantly at day 9 with a
higher cure rate in participants of male sex (59.3% in
females and 94.1% in males; p < 0.01) and with shorter
hair (90.5%, 69.2% and 54.1% for short, middle-sized
and long hair, respectively, p = 0.02).
Secondary outcomes
Degree of itching (on an ordinal scale from 0 to 4) was
reduced similarly in both treatment groups (Table 4).
Both treatments were perceived as cosmetically pleasant
with a significantly better acceptance of dimeticone at
days 4, 7 and 9 (Table 5).
Frequency of cervical lymphadenopathy decreased simi-
larly in both groups during the study period (Table 6).
Bacterial superinfection was rare and not observed on day
7 or later.
Adverse events
The number of participants experiencing any adverse
events was similar in both groups, and only two product-
related incidents occurred.
In the dimeticone group, 29 adverse events were reported
in 25 participants. Of these, two were related to treatment
(ocular irritation). The liquid had entered into the eyes
after topical application. The irritation resolved spontane-
ously in both cases after washing the eyes with clean
water. The other events were classified as unrelated or
unlikely to the study (such as superficial wounds after
falls, headache etc.).
In the permethrin group, 32 adverse events were reported
in 26 participants, all of them unrelated or unlikely to be
related to treatment.
Discussion
Our study shows that a product containing a high percent-
age of dimeticone (a parallel formulation of NYDA®) is
significantly more effective in curing head lice infestations
than permethrin lotion (Kwell®). Dimeticone reduced the
degree of itching similar to permethrin and had a higher
cosmetic acceptability.
BMC Infectious Diseases 2008, 8:115 http://www.biomedcentral.com/1471-2334/8/115
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Flow of participants through each stage of the trialigure 2
Flow of participants through each stage of the trial.
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In contrast to the high cure rates in the dimeticone group,
cure rates in the permethrin group were 67% and 68% at
days 2 and 9. Interestingly, in two recent trials from the
UK assessing the efficacy of 4% dimeticone, cure rates of
about 70% were reported, but in moderately infested indi-
viduals, cure rates were only 39% and 64%, respectively
[17,18]. In our study, in the dimeticone group cure rates
were not influenced by the intensity of infestation, con-
trary to the permethrin group.
It may be argued that in countries where resistance to per-
methrin or malathion has been known since long, such as
in the UK, a dimeticone product may perform better, sim-
ply because a part of the head lice population would be
resistant to insecticides. We believe that the difference in
efficacy observed between dimeticone and permethrin in
our study reflects the failure of permethrin to kill all head
lice on the scalp. This resulted in persistence of infestation
in the children treated with this pediculicide, particularly
when the intensity of infestation was high. However, we
are aware that permethrin resistance cannot be ruled out
– although it seems unlikely – because resistance of head
lice to insecticides has never been studied systematically
in northeast Brazil.
Seven days after the first application, cure rates were con-
siderably lower. This observation can be attributed mainly
to reinfestation initiated by children who had remained
infested after the first treatment: the vast majority of those
study participants that were cured on day 2, but infested
on day 7, had vital adult lice detected on this day. As adult
head lice found up to one week after cure by definition
derive from reinfestation (no newly hatched nymphs can
develop into adults within one week) [21,24,25], we
believe that the increase in the number of infested chil-
dren seven days after first application is caused mainly by
reinfestation and not by a low ovicidal activity of dimeti-
cone. Children played together during the day, frequently
had intimate body contact and slept together in dormito-
ries, irrespective to which treatment group they belonged
to. Hence, our data not only show the comparative effi-
cacy of the two tested compounds, but also the effective-
ness of head lice treatment in the setting of a holiday
resort.
Other studies also provided evidence that reinfestation is
common if study participants are not completely cured, or
if they stay in close contact to other infested people
[17,18]. In fact, we observed in another study that NYDA®
reduced hatch rates of eggs to < 4% after 60 min incuba-
tion, as compared to a hatch rate of 80% in eggs treated
with 0.5% permethrin alcoholic solution (Heukelbach,
unpublished data). A few children had mixed stages
including nymphs (data not shown). As larval stages were
not further defined during the study, we were unable to
Table 1: Baseline demographic and clinical characteristics of both treatment groups
Dimeticone group
(n = 73)
Permethrin group
(n = 72)
P value
Sex:
Male 54 (74.0%) 55 (76.4%)
Female 19 (26.0%) 17 (23.6%) P = 0.7
Age (years):
Median (interquartile range) 10 (7–12) 10 (8.5–12) P = 0.2
Intensity of infestation*
Median (interquartile range) 4 (2–12) 6 (2–14) P = 0.5
Hair length:
Short 21 (28.8%) 21 (29.2%)
Middle-sized 16 (21.9%) 13 (18.1%)
Long 36 (49.3%) 38 (52.8%) P = 0.8
*Number of lice found during three minutes of visual inspection. Inspection was stopped when 25 vital lice were found.
Table 2: Cure rates, defined as the complete absence of active lice.
Dimeticone group Permethrin group P value Effect size
Cured/total % (95% CI) Cured/total % (95% CI) RR (95% CI)
Day 2 69/73 94.5% (86.6% – 98.5%) 48/72 66.7% (54.6% – 77.3%) P < 0.0001 1.42 (1.19–1.68)
Day 7 47/73 64.4% (53.3% – 75.3%) 43/72 59.7% (47.5% – 71.1%) P = 0.5 1.22 (0.59–2.52)
Day 9 70/72 97.2% (90.3% – 99.7%) 48/71 67.6% (55.4% – 78.2%) P < 0.0001 1.44 (1.22–1.70)
Topical treatments were applied on days 1 and 8.
BMC Infectious Diseases 2008, 8:115 http://www.biomedcentral.com/1471-2334/8/115
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prove that in some cases eggs may have not been killed by
the initial treatment.
Dimeticones are regarded as chemically inert and non-
toxic, and are components of many cosmetic skin and hair
care products. Since the mode of action of dimeticones is
physical, development of resistance is unlikely. Besides,
the repeated applications are not expected to increase the
risk for adverse events. The two randomized clinical trials
recently performed in the UK compared dimeticone in a
concentration of only 4% (Hedrin®) with α-phenotrin
and malathion, respectively [17,18]. We opted to assess
the therapeutic efficacy of a product containing a 92%
mixture of two dimeticones of different viscosity (a low
viscosity, also at room temperature more readily volatile
dimeticone, responsible for the highly creeping and
spreading properties of the product, and a higher viscos-
ity, less volatile dimeticone) in an environment where the
intensity of infestation was extremely high. As NYDA® is
claimed to kill lice by entering into the spiracles and fill-
ing the tracheal system with subsequent blocking of the
oxygen supply [14,15], it can be assumed that the high
creeping and spreading properties of the product in con-
nection with the high percentage of the more viscous
dimeticone component in NYDA® is responsible for the
increased cure rates, as compared to Hedrin®. In fact, we
have shown that NYDA® killed all lice in vitro, collected
from individuals living in the community where our par-
ticipants were recruited from, and that it performed better
than 4% dimeticone (Hedrin®) [16].
Our study is subject to limitations. Usually, a period of 14
days is recommended for the final assessment, to detect all
lice hatching from eggs not killed by the products [21,26].
However, we had perceived in discussions with commu-
nity representatives prior to the study that neither parents
nor children would have agreed to a prolongation of the
stay in the resort for more than 10 days. Thus, we could
not adhere to recommendations made previously and
opted to perform the final assessment after nine days.
In the dimeticone group we observed only two adverse
events related to the use of the product. The product had
entered the eyes and caused mild irritation which resolved
quickly. We conclude that the dimeticone-based product
is a safe pediculicide. Dimeticones are physiologically
inert and non-toxic silicone oils. They are widely used in
cosmetic products to facilitate the use of a comb and to
Table 3: Cure rates stratified according to infestation intensity (assessed by 3 minutes of visual inspection before treatment)
Dimeticone group Permethrin group P value Effect size
Cured/total % (95% CI) Cured/total % (95% CI) RR (95% CI)
Low or moderate infestationa
Day 2 37/38 97.4% (86.2% – 99.9%) 23/31 74.2% (55.4% – 88,1%) P = 0.004 1.31 (1.06–1.63)
Day 7 32/38 84.2% (68.7% – 94.0%) 23/31 74.2% (55.4% – 88,1%) P = 0.3 1.14 (0.88–1.46)
Day 9 36/37 97.3% (85.5% – 99.9%) 25/31 80.6% (62.5% – 92.5%) P = 0.02 1.21 (1.01–1.45)
Heavy infestationb
Day 2 32/35 91.4% (76.9% – 98.2%) 25/41 61.0% (44.5% – 75.8%) P = 0.002 1.50 (1.15–1.95)
Day 7 15/35 42.9% (26.3% – 60.4%) 20/41 48.8% (32.9% – 64.9%) P = 0.6 0.88 (0.54–1.44)
Day 9 34/35 97.1% (85.1% – 99.9%) 23/40 57,5% (40.9% – 73.0%) P < 0.0001 1.69 (1.29–2.22)
a < 5 active head lice at the beginning of the study; see material and methods
b ≥ 5 active head lice
Table 4: Degree of itching, assessed by an ordinal visual scale from 0 to 4 (see Methods)
Dimeticone group Permethrin group P value
Median (interquartile range) Median (interquartile range)
Before treatment 2 (1–4) 2 (1–3) p = 0.02
6 h after treatment 1 (0–1) 1 (0–1) P = 0.8
24 h after treatment (day 2) 1 (0–1) 1 (0–1) P = 0.6
Day 3 1 (0–1) 1 (0–1) P = 0.07
Day 4 1 (0–1) 0 (0–1) P = 0.8
Day 5 1 (0–1) 0 (0–1) P = 0.13
Day 6 1 (0–1) 0 (0–1) P = 0.13
Day 7 1 (0–1) 1 (0–1) P = 0.14
Day 8 1 (0–1) 0 (0–1) P = 0.3
Day 9 0 (0–1) 0 (0–1) P = 0.5
BMC Infectious Diseases 2008, 8:115 http://www.biomedcentral.com/1471-2334/8/115
Page 9 of 10
(page number not for citation purposes)
make the hair silky and soft [27]. After oral ingestion, the
oil is not absorbed but eliminated unaltered in the faeces.
Oral dimeticones are used as anti-flatulents to alleviate
gastrointestinal discomfort.
Non-insecticidal treatment options against head lice
infestations are limited and include some natural prod-
ucts with good efficacy [28,29], but also physical methods
and home remedies with rather low efficacy, such as
combing with a fine tooth comb or application of vinegar
[30-34]. The dimeticone product, being highly efficacious
and non-toxic, can be considered an ideal pediculicide. It
is acceptable for individuals who do not want to use insec-
ticides with a neurotoxic potential and for those who look
for a high cosmetic acceptability. A recent study has
shown that time necessary to treat children with head lice
infestations is an important aspect for parents to opt for
one or another therapy [35]. As efficacy of dimeticone was
very high without using a head louse comb, dimeticone
will also be ideal for those parents who find combing
nasty and time consuming.
Conclusion
The dimeticone-based head lice product (similar to the
branded product NYDA®) is an efficacious alternative to
chemical pediculicides with no inherent risk for develop-
ment of resistance. The cure rate was >97%, even in indi-
viduals with a high intensity of infestation. Severity of
itching was reduced to negligible.
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Table 5: Cosmetic acceptability of products (minimum score: -4; maximum score: +4; see Methods)
Dimeticone group Permethrin group P value
Median (interquartile range) Median (interquartile range)
Day 2 1 (0 – 2) 1 (-1 – 2) P = 0.5
Day 4 1 (0 – 2) 0 (-0.5 – 1) P = 0.003
Day 7 1 (1 – 2) 1 (0 – 2) P = 0.04
Day 9 1 (1 – 2) 1 (-1 – 2) P = 0.01
Table 6: Clinical pathology in both treatment groups
Dimeticone group
n (%)
Permethrin group
n (%)
P value
Cervical lymphadenopathy:
Before treatment 49/73 (67.1%) 54/72 (75.0%) P = 0.3
Day 2 51/73 (69.9%) 52/72 (72.2%) P = 0.8
Day 4 52/73 (71.2%) 49/72 (68.1%) P = 0.7
Day 7 39/73 (53.4%) 46/72 (63.9%) P = 0.2
Day 9 41/72 (56.9%) 45/71 (63.4%) P = 0.7
Bacterial superinfection of lesions:
Before treatment 1/73 (1.4%) 0/72 (0%) P = 0.3
Day 2 1/73 (1.4%) 1/72 (1.4%) P = 1.0
Day 4 1/73 (1.4%) 0/72 (0%) P = 0.3
Day 7 0/73 (0%) 0/72 (0%) P = 1.0
Day 9 0/72 (0%) 0/71 (0%) P = 1.0
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